H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 83 Citations 21,399 367 World Ranking 8358 National Ranking 98

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

Nils Brünner spends much of his time researching Internal medicine, Cancer, Pathology, Breast cancer and Endocrinology. Nils Brünner has included themes like Gastroenterology and Oncology in his Internal medicine study. The study incorporates disciplines such as Hematology, Immunology and Enzyme inhibitor in addition to Cancer.

The concepts of his Pathology study are interwoven with issues in Cancer cell, Prognostic variable and Survival analysis. His study in Breast cancer is interdisciplinary in nature, drawing from both Malignancy, Metastasis, Chemotherapy and Cancer biomarkers. His Endocrinology research incorporates elements of Receptor, Progesterone receptor, Estrogen receptor and Cell growth.

His most cited work include:

  • Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization (635 citations)
  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. (517 citations)
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers (444 citations)

What are the main themes of his work throughout his whole career to date?

Nils Brünner focuses on Internal medicine, Cancer, Oncology, Breast cancer and Colorectal cancer. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Pathology. His study looks at the relationship between Endocrinology and fields such as Estrogen receptor, as well as how they intersect with chemical problems.

His studies in Cancer integrate themes in fields like Molecular biology, Cancer research and Blood plasma. His research integrates issues of Matrix metalloproteinase, Primary tumor, Disease and Hazard ratio in his study of Oncology. His Colorectal cancer study incorporates themes from Stage, Carcinoembryonic antigen and Bioinformatics.

He most often published in these fields:

  • Internal medicine (54.58%)
  • Cancer (37.85%)
  • Oncology (29.68%)

What were the highlights of his more recent work (between 2013-2021)?

  • Internal medicine (54.58%)
  • Colorectal cancer (26.29%)
  • Cancer (37.85%)

In recent papers he was focusing on the following fields of study:

Nils Brünner mainly focuses on Internal medicine, Colorectal cancer, Cancer, Oncology and Cancer research. His research links Gastroenterology with Internal medicine. His Colorectal cancer research includes elements of Prospective cohort study, Phases of clinical research and Bioinformatics.

His Cancer research is multidisciplinary, incorporating perspectives in Drug resistance and Pathology. In his research, Cetuximab is intimately related to KRAS, which falls under the overarching field of Oncology. His Cancer research study also includes

  • Cancer cell which is related to area like Multiple drug resistance,
  • Cell together with Glioma.

Between 2013 and 2021, his most popular works were:

  • Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer (364 citations)
  • Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance (116 citations)
  • lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells. (62 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His primary areas of investigation include Cancer research, Cancer, Colorectal cancer, Breast cancer and Internal medicine. His work carried out in the field of Cancer research brings together such families of science as Cell, Copy-number variation, Pathology, Gene and Immunofluorescence. His Cancer research is multidisciplinary, incorporating elements of Immunohistochemistry, Protein kinase B, PI3K/AKT/mTOR pathway and CD44.

His work deals with themes such as Prospective cohort study, Bioinformatics and Confidence interval, which intersect with Colorectal cancer. His research integrates issues of Mutation, Epithelial–mesenchymal transition, microRNA and Docetaxel in his study of Breast cancer. Nils Brünner interconnects Gastroenterology, Surgery, Oncology and Genetic marker in the investigation of issues within Internal medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

Khalid Bajou;Agnès Noël;R. D. Gerard;Véronique Masson.
Nature Medicine (1998)

851 Citations

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)

734 Citations

The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients

John A. Foekens;Harry A. Peters;Maxime P. Look;Henk Portengen.
Cancer Research (2000)

540 Citations

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Jan Grøndahl-Hansen;Ib Jarle Christensen;Christian Rosenquist;Nils Brünner.
Cancer Research (1993)

507 Citations

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Catharine M. Sturgeon;Michael J. Duffy;Ulf Håkan Stenman;Hans Lilja.
Clinical Chemistry (2008)

444 Citations

Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

Jun Yu;Qiang Feng;Sunny Hei Wong;Dongya Zhang.
Gut (2017)

434 Citations

Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue

Helle Pedersen;Nils Brünner;Dorthe Francis;Kell Østerlind.
Cancer Research (1994)

429 Citations

The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies

Khalid Bajou;Véronique Masson;Robert D. Gerard;Petra M. Schmitt.
Journal of Cell Biology (2001)

400 Citations

The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion

K. Danø;N. Behrendt;N. Brunner;V. Ellis.
Fibrinolysis and Proteolysis (1994)

377 Citations

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

Ross W. Stephens;Hans Jørgen Nielsen;Ib J. Christensen;Ole Thorlacius-Ussing.
Journal of the National Cancer Institute (1999)

354 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Nils Brünner

Manfred Schmitt

Manfred Schmitt

Technical University of Munich

Publications: 86

Ib Jarle Christensen

Ib Jarle Christensen

University of Copenhagen

Publications: 69

Janko Kos

Janko Kos

University of Ljubljana

Publications: 57

Michael J. Duffy

Michael J. Duffy

University College Dublin

Publications: 54

Agnès Noël

Agnès Noël

University of Liège

Publications: 46

John A. Foekens

John A. Foekens

Erasmus University Rotterdam

Publications: 43

Viktor Magdolen

Viktor Magdolen

Technical University of Munich

Publications: 42

Keld Danø

Keld Danø

Copenhagen University Hospital

Publications: 42

Eleftherios P. Diamandis

Eleftherios P. Diamandis

Mount Sinai Hospital

Publications: 38

Michael Ploug

Michael Ploug

University of Copenhagen

Publications: 37

Peter Carmeliet

Peter Carmeliet

KU Leuven

Publications: 35

Donald C. McMillan

Donald C. McMillan

Glasgow Royal Infirmary

Publications: 34

Erik W. Thompson

Erik W. Thompson

Queensland University of Technology

Publications: 34

Francesco Blasi

Francesco Blasi

University of Milan

Publications: 32

Peter A. Andreasen

Peter A. Andreasen

Aarhus University

Publications: 32

Something went wrong. Please try again later.